The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 828 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 26 August 2022 | Discontinued. The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended. |
| 06 February 2018 | Suspended. The company has been unable to make a submission to NICE in accordance with the current timelines for this appraisal. We will therefore suspend the appraisal until further notice and the committee discussion scheduled for 17 April 2018 will not take place. We will continue to monitor the situation and will update you on the next steps for this appraisal as soon as possible. |
| 03 November 2017 | Invitation to participate |
| 25 January 2017 | Draft scope documents |
| 05 December 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual